Financings in Brief: Inhale Therapeutic Systems
This article was originally published in The Gray Sheet
Executive Summary
Inhale Therapeutic Systems: Completes $32.4 mil. private placement of 1.8 mil. common shares at $18 each. Vector Securities International was placement agent for the financing. Proceeds will go toward "expansion of production capabilities and facilities" and development of a drug delivery system to allow pulmonary delivery of "a wide range of drugs, including macromolecules...for systemic and local lung indications," the firm states. Clinical trials using the system in conjunction with four different drugs are under way. The Palo Alto, California-based firm has "feasibility and development partnerships" with several firms, including Baxter, Pfizer, Centeon, Genzyme, Asahi and Lilly...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.